SCHEMBL6437530

SCHEMBL6437530

Brc1cccc(OCCOCc2ccccc2)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 1/20 0.53
TSHR P16473 1/20 0.47
MAOB P27338 2/20 0.40
MAOA P21397 1/20 0.40
NAAA Q02083 1/20 0.39
ALOX5 P09917 1/20 0.37
MAPT P10636 2/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
ALDH1A1 P00352 1/20 0.36
HPGD P15428 1/20 0.36
HRH4 Q9H3N8 1/20 0.35
HRH3 Q9Y5N1 1/20 0.35
GABRG2 P18507 1/20 0.35
GABRB3 P28472 1/20 0.35
GABRA5 P31644 1/20 0.35
GABRA3 P34903 1/20 0.35
TRPV3 Q8NET8 1/20 0.35
KDM4E B2RXH2 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29574709 0.85 HTR7 (0.51) HTR7TSHRMAOBALOX5MAPT
SCHEMBL5183 0.85 HTR7 (0.51) HTR7TSHRMAOBALOX5MAPT
SCHEMBL4688 0.82 HTR7 (0.57) HTR7ALOX5NPC1RAB9ASMN1; SMN2
SCHEMBL31638025 0.79 HTR7 (0.39) HTR7TSHRMAOBMAOANAAA
SCHEMBL6377587 0.79 HTR7 (0.61) HTR7MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL31637886 0.78 HTR7 (0.55) HTR7MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL31637889 0.78 HTR7 (0.55) HTR7MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL18355063 0.78 HTR7 (0.55) HTR7MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL31637912 0.78 HTR7 (0.55) HTR7MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL16943121 0.78 HTR7 (0.55) HTR7MAPTNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050026836-A1 Composition for the treatment of damaged tissue DACK KEVIN NEIL (GB) 2005-02-03 US disclosed
US-20030199440-A1 Composition for the treatment of damaged tissue PFIZER INC. 2003-10-23 US disclosed
EP-1181017-B1 METALLOPROTEASE INHIBITORS PFIZER LTD (GB) 2003-04-16 EP disclosed
US-6511993-B1 Substituted alpha-aminosulphonyl-acetohydroxamic acids which are inhibitors of zinc-dependent metalloprotease enzymes PFIZER INC. 2003-01-28 US disclosed
EP-1242120-A2 COMBINATIONS OF GROWTH FACTORS AND I:UPA OR I:MMP FOR THE TREATMENT OF DAMAGED TISSUE Pfizer Limited (GB) 2002-09-25 EP disclosed
EP-1181017-A1 METALLOPROTEASE INHIBITORS Pfizer Limited (GB) 2002-02-27 EP disclosed
WO-2001049309-A2 COMBINATIONS OF GROWTH FACTORS AND I: UPA OR I: MMP FOR THE TREATMENT OF DAMAGED TISSUE PFIZER LIMITED (GB) 2001-07-12 WO disclosed
WO-2000074681-A1 METALLOPROTEASE INHIBITORS PFIZER LIMITED (GB) 2000-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199440-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 HTR7 3967/4885TSHR 4346/4885MAOB 2075/4885
US-20050026836-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 HTR7 3967/4885TSHR 4346/4885MAOB 2075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.